Tsitsilonis O - Search Results

1

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity.

Kostopoulos IV, Fotiou D, Gavriatopoulou M, Rousakis P, Ntanasis-Stathopoulos I, Panteli C, Malandrakis P, Migkou M, Angelis N, Kanellias N, Eleutherakis-Papaiakovou E, Theodorakakou F, Krevvata M, Terpos E, Dimopoulos MA, Tsitsilonis O, Kastritis E. Kostopoulos IV, et al. Among authors: tsitsilonis o. Blood Cancer J. 2024 Feb 6;14(1):26. doi: 10.1038/s41408-024-00988-x. Blood Cancer J. 2024. PMID: 38321005 Free PMC article. No abstract available.

2

Prothymosin alpha: efficient sequence determination by experimental and theoretical capillary electrophoretic support.

Weiler A, Stoeva S, Tsitsilonis OE, Voelter W. Weiler A, et al. Among authors: tsitsilonis oe. Electrophoresis. 1997 May;18(5):757-61. doi: 10.1002/elps.1150180516. Electrophoresis. 1997. PMID: 9194602

3

Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.

Baxevanis CN, Gritzapis AD, Spanakos G, Tsitsilonis OE, Papamichail M. Baxevanis CN, et al. Among authors: tsitsilonis oe. Cancer Immunol Immunother. 1995 Jun;40(6):410-8. doi: 10.1007/BF01525392. Cancer Immunol Immunother. 1995. PMID: 7543022 Free PMC article.

4

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Baxevanis CN, et al. Among authors: tsitsilonis oe. J Immunol. 2000 Apr 1;164(7):3902-12. doi: 10.4049/jimmunol.164.7.3902. J Immunol. 2000. PMID: 10725753

5

Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha.

Klimentzou P, Paravatou-Petsotas M, Zikos C, Beck A, Skopeliti M, Czarnecki J, Tsitsilonis O, Voelter W, Livaniou E, Evangelatos GP. Klimentzou P, et al. Among authors: tsitsilonis o. Peptides. 2006 Jan;27(1):183-93. doi: 10.1016/j.peptides.2005.07.002. Epub 2005 Sep 14. Peptides. 2006. PMID: 16150512

6

Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils.

Karachaliou CE, Liolios C, Triantis C, Zikos C, Samara P, Tsitsilonis OE, Kalbacher H, Voelter W, Papadopoulos M, Pirmettis I, Livaniou E. Karachaliou CE, et al. Int J Pharm. 2015;486(1-2):1-12. doi: 10.1016/j.ijpharm.2015.03.031. Epub 2015 Mar 18. Int J Pharm. 2015. PMID: 25796124

7

A skeletal muscle troponin T specific ELISA based on the use of an antibody against the soluble troponin T (16-31) fragment.

Tsitsilonis OE, Stoeva S, Echner H, Balafas A, Margomenou L, Katsoulas HL, Troy DJ, Voelter W, Papamichail M, Lymberi P. Tsitsilonis OE, et al. J Immunol Methods. 2002 Oct 15;268(2):141-8. doi: 10.1016/s0022-1759(02)00186-2. J Immunol Methods. 2002. PMID: 12215382

8

Solid-phase synthesis of a peptide derivative of thymosin alpha1 and initial studies on its (99m)Tc-radiolabelling.

Klimentzou P, Beck A, Varvarigou A, Tsitsilonis O, Voelter W, Pirmettis I, Papadopoulos M, Livaniou E, Zikos C. Klimentzou P, et al. Among authors: tsitsilonis o. Chem Biol Drug Des. 2007 Jul;70(1):40-6. doi: 10.1111/j.1747-0285.2007.00529.x. Chem Biol Drug Des. 2007. PMID: 17630993

9

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA. Bamias A, et al. Among authors: tsitsilonis o. Gynecol Oncol. 2008 Feb;108(2):421-7. doi: 10.1016/j.ygyno.2007.10.018. Epub 2007 Nov 26. Gynecol Oncol. 2008. PMID: 18036640

10

VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2.

Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, Dimopoulos MA, Bamias A. Ziogas AC, et al. Among authors: tsitsilonis o. Int J Cancer. 2012 Feb 15;130(4):857-64. doi: 10.1002/ijc.26094. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21445972

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters